Abstract:The inflammatory cell model of human mononuclear macrophage (THP‐1) cells induced by lipopolysaccharide (LPS) was established to study the effect of Dexmedetomidine (DEX) on the expression of cell‐related inflammatory factors. ADRA2A gene knockout THP‐1 cells (THP‐1KO) were constructed, and the effect of DEX on the expression of inflammatory factors of THP‐1KO cells was detected. The target sites of DEX on β2 AR were screened by molecular docking. Reversion experiments were performed using ADRB2siRNA. The results showed that DEX significantly decreased the expression of MCP‐1, interleukin‐06, and IL‐8 in THP‐1 and THP‐1KO cells induced by the LPS, and increased the level of IL‐10. Immunofluorescence results showed that β2 adrenergic receptor (β2 AR) expression increased after DEX treatment. DEX significantly increased the activation of β2 AR and PKA/CREB pathways, inhibited the activation of NF‐κB. ADRB2 siRNA reversed the effects of DEX and promoted the release of inflammatory cytokines Introduction Dexmedetomidine (DEX) is primarily utilized for sedation in the context of general anesthesia or intensive care. However, the exact regulatory mechanism by which DEX affects cytokines remains unclear. This study aims to investigate the underlying mechanism by which DEX inhibits proinflammatory factors through activation of the β2 adrenergic receptor (β2 AR). Methods The inflammatory cell model of human mononuclear macrophage (THP‐1) cells induced by lipopolysaccharide (LPS) was established to study the effect of DEX on the expression of cell‐related inflammatory factors. ADRA2A gene knockout THP‐1 cells (THP‐1KO) were constructed by CRISPR technology, and the effect of DEX on the expression of inflammatory factors of THP‐1KO cells was detected. The target sites of DEX on β2 AR were screened by molecular docking. Reversion experiments were performed using ADRB2‐siRNA. Western blot was used to detect the activation of β2 AR/PKA/CREB pathway and NF‐κB, and ELISA was used to detect the release level of inflammatory factors. Results The results demonstrated a significant reduction in the expression levels of MCP‐1, interleukin‐06, and IL‐8 in both THP‐1 and THP‐1KO cells when induced by LPS following treatment with DEX. Additionally, DEX treatment led to an increase in IL‐10 expression. Immunofluorescence analysis revealed an upregulation of β2 AR expression after DEX treatment. Western blot results indicated that DEX notably enhanced the activation of the β2 AR and PKA/CREB pathways, while concurrently suppressing the activation of NF‐κB. Notably, the use of ADRB2 siRNA reversed the effects of DEX treatment and promoted the release of inflammatory cytokines. Conclusion DEX initiates the activation of the PKA/CREB pathway through the activation of β2 AR. Simultaneously, it exerts an inhibitory effect on the activation of NF‐κB, consequently reducing the transcription of proinflammatory factors while increasing the transcription of anti‐inflammatory factors.

[Inhibitory Effect of Dexamethasone on Myeloid Differentiation Factor 88 and Tumor Necrosis Factor-Alpha Expressions in Mouse Peritoneal Macrophages].

Dexamethasone Inhibits S. Aureus-Induced Neutrophil Extracellular Pathogen-Killing Mechanism, Possibly Through Toll-Like Receptor Regulation

The in Vitro Fungicidal Activity of Human Macrophages Against Penicillium Marneffei is Suppressed by Dexamethasone.

Comparative analysis of the effects of cyclophosphamide and dexamethasone on intestinal immunity and microbiota in delayed hypersensitivity mice

Dexmedetomidine activates the PKA/CREB pathway and inhibits proinflammatory factor expression through β2 adrenergic receptors

Dexamethasone pretreatment reduces isoproterenol-induced myocardial injury and the expression of TNF-α

Peucedanum Praeruptorum Dunn Polysaccharides Regulate Macrophage Inflammatory Response Through TLR2/TLR4-mediated MAPK and NF-κB Pathways.

[Anti-Oxidative Effects of Dexamethasone on Mice with Experimental Autoimmune Encephalomyelitis].

Dexmedetomidine alleviates intestinal barrier dysfunction and inflammatory response in mice via suppressing TLR4/MyD88/NF-κB signaling in an experimental model of ulcerative colitis

Dexmedetomidine Protects against Airway Inflammation and Airway Remodeling in a Murine Model of Chronic Asthma through TLR4/NF-κB Signaling Pathway

EFFECTS OF CRUDE POLYSACCHARIDES EXTRACT FROM MYTILUS EDULIS ON THE IMMUNE FACTORS IN IMMUNOSUPPRESSED MICE

Effect of dehydroepiandrosterone on the immune function of mice in vivo and in vitro.

High-dose dexamethasone induced LPS-stimulated rat alveolar macrophages apoptosis

Dexmedetomidine alleviates airway hyperresponsiveness and allergic airway inflammation through the TLR4/NF-κB signaling pathway in mice

Dexmedetomidine Promotes Lipopolysaccharide-Induced Differentiation of Cardiac Fibroblasts and Collagen I/III Synthesis through α2A Adrenoreceptor-Mediated Activation of the PKC-p38-Smad2/3 Signaling Pathway in Mice

Effects of Dexamethasone on Alveolar Fluid Clearance in Mouse Asthma Models

Mechanism of Dexamethasone Inhibiting U937 Cell Adhesion and Phagocytose Function

Effects of Dexamethasone on Acute Myocardial Injury induced by Isoproterenol and T Cells in Spleen

Cdna Microarray Analysis of the Differentially Expressed Genes Involved in Murine Pre-Osteoclast RAW264.7 Cells Proliferation Stimulated by Dexamethasone

Dexamethasone and lactoferrin induced PMN-MDSCs relieved inflammatory adverse events of anti-cancer therapy without tumor promotion

In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway.